tldrdailynews.com logo

KRAS-targeted therapy extends life in pancreatic cancer, signaling a new era

1 min read
Source: statnews.com
KRAS-targeted therapy extends life in pancreatic cancer, signaling a new era
Photo: statnews.com
TL;DR Summary

A pancreatic cancer patient on Revolution Medicines' KRAS inhibitor daraxonrasib reports a dramatic extension of life, illustrating how targeting historically 'undruggable' KRAS can yield durable benefits and fueling optimism for KRAS inhibitors across pancreatic and other KRAS-mutant cancers.

Topics:business#clinical-trials#health#kras#pancreatic-cancer#revolution-medicines#targeted-therapy
Share this article
The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades  statnews.com

Reading Insights

Total Reads

0

Unique Readers

20

Time Saved

3 min

vs 3 min read

Condensed

93%

569 → 38 words

Want the full story? Read the original article

Read on statnews.com